A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

Study Number
1391721
Phase
I/II
Age Group
Adult
Principal Investigator
Emese Zsiros
Purpose

This research study is studying a new drug, NC762, as a possible treatment for advanced or metastatic solid tumors.

Check your eligibility for this trial
Check now
Full Title

NC762-01 A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects with Advanced or Metastatic Solid Tumors

ClinicalTrials.Gov ID
NCT04875806

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.